• 1. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 2. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 3. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 4. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 5. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053

The Role of 5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid (CAS No. 1203498-99-0) in Modern Chemical and Pharmaceutical Research

5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid, a structurally unique heterocyclic compound with the CAS registry number 1203498-99-0, has emerged as a focal point in recent advancements within medicinal chemistry and pharmacological exploration. This molecule belongs to the broader class of pyrrolopyridine derivatives, characterized by its fused bicyclic core comprising a pyrrole ring and a pyridine ring. The presence of a chlorine substituent at the 5-position of the pyrrolopyridine scaffold, coupled with the carboxylic acid group at position 3, imparts distinctive physicochemical properties that are critical for its biological activity and synthetic versatility. Recent studies have highlighted its potential as a lead compound in drug discovery programs targeting oncology and neurodegenerative diseases, driven by its ability to modulate key cellular pathways without significant off-target effects.

In 2023, researchers from the University of Cambridge demonstrated that this compound exhibits selective inhibition of histone deacetylase 6 (HDAC6), an enzyme increasingly recognized for its role in cancer progression and neuroprotection. The chlorine atom at position 5 was shown to enhance binding affinity through favorable π-interactions with the enzyme's hydrophobic pocket, as revealed by X-ray crystallography studies published in Nature Communications. This structural feature also contributes to improved aqueous solubility compared to non-chlorinated analogs, addressing a common challenge in drug formulation development. The carboxylic acid moiety further enables facile conjugation with biocompatible carriers or prodrug linkers, expanding its applicability in targeted delivery systems.

Synthetic chemists have optimized the preparation of 5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid using microwave-assisted protocols reported in the Journal of Medicinal Chemistry. By employing copper-catalyzed cyclocondensation reactions under solvent-free conditions, researchers achieved >95% purity yields while reducing reaction times by 60% compared to conventional methods. This advancement aligns with current industry trends toward sustainable synthesis practices outlined in recent green chemistry guidelines issued by ACS Publications.

Clinical pharmacology investigations published in early 2024 revealed promising antiproliferative activity against triple-negative breast cancer cell lines (MDA-MB-231) with IC?? values as low as 0.8 μM. Unlike traditional chemotherapy agents that indiscriminately target rapidly dividing cells, this compound selectively induces apoptosis through HDAC6 inhibition without affecting normal epithelial cells at therapeutic concentrations. Mechanistic studies using CRISPR-Cas9 knockout models confirmed HDAC6 dependency for cytotoxic effects, providing robust validation for its proposed mode of action.

In neurodegenerative research applications, this compound has shown neuroprotective properties in α-synuclein-induced Parkinson's disease models. A collaborative study between MIT and Pfizer demonstrated that it mitigates microglial activation by inhibiting NFκB signaling pathways while promoting autophagy via HDAC6-dependent mechanisms. These dual actions suggest potential synergistic effects when combined with existing therapies targeting protein aggregation pathologies.

The structural flexibility of CAS No. 1203498-99-0 allows for rational design modifications to enhance therapeutic indices. Researchers at Stanford have synthesized fluorinated derivatives where the chlorine substituent is replaced with trifluoromethyl groups at position 5 and 7, resulting in improved blood-brain barrier permeability without compromising HDAC6 selectivity. These findings were presented at the 2024 American Chemical Society National Meeting and underscored the importance of positional substitution patterns on both efficacy and pharmacokinetic profiles.

Bioavailability optimization studies conducted by Merck scientists employed nanoparticle encapsulation techniques to address solubility limitations inherent to carboxylic acid-containing compounds. Their work published in Bioconjugate Chemistry demonstrated that PEGylated liposomal formulations achieved plasma concentrations exceeding those required for efficacy while minimizing hepatic metabolism pathways typically associated with pyrrolopyridines.

Safety evaluations based on OECD guidelines have confirmed low acute toxicity profiles up to doses exceeding 5 g/kg in preclinical models. Chronic administration studies over 16 weeks showed no significant organ toxicity or mutagenic effects when tested against standard Ames assays and micronucleus tests according to recent data from Drug Discovery Today supplements.

The unique combination of structural features - including the chlorinated pyrrolopyridine ring system (CAS No. 1203498-99-0) - positions this compound favorably for further development across multiple therapeutic areas. Its documented ability to cross cell membranes efficiently while maintaining enzymatic selectivity addresses critical challenges faced during early drug discovery stages.

Ongoing research initiatives are exploring its application as a scaffold for multi-target inhibitors targeting both HDAC6 and PI3K/Akt/mTOR pathways simultaneously. Preliminary data from these efforts suggest enhanced efficacy against treatment-resistant glioblastoma multiforme cell lines when compared to monotherapy approaches reported in current clinical trials.

Spectroscopic analysis confirms the compound's planar molecular structure with conjugated π-electron systems that facilitate favorable drug-receptor interactions as predicted by molecular docking simulations validated against experimental binding data from multiple institutions including NIH-funded laboratories.

Nuclear magnetic resonance (NMR) studies reveal distinct chemical shift patterns at δ ppm values corresponding to chlorine-substituted aromatic protons (δ 7.8–8.4 ppm) and carboxylic acid signals (δ 17 ppm region), providing unambiguous structural confirmation required for regulatory submissions under ICH Q7 guidelines.

Innovative applications now under investigation include use as a fluorescent probe precursor due to its inherent UV-absorbing properties when coupled with quantum dot materials through carbodiimide-mediated coupling reactions described in Advanced Materials recent special issues on bioimaging agents.

Mechanistic insights gained from cryo-electron microscopy reveal conformational changes induced upon binding to HDAC6's catalytic domain that stabilize enzyme-inhibitor complexes longer than previously observed bispecific inhibitors according to findings presented at EACS annual conferences last year.

Preliminary toxicokinetic data indicate rapid clearance via renal excretion pathways without accumulation risks when administered intravenously or orally according to phase I equivalent preclinical models developed at GlaxoSmithKline's research facilities published recently in Clinical Pharmacology & Therapeutics journal supplements.

The compound's synthesis pathway involves sequential nitration followed by Suzuki-Miyaura cross-coupling steps using palladium catalysts under controlled temperature regimes between -10°C and room temperature conditions optimized through high-throughput experimentation platforms described in Green Chemistry's latest issue on scalable synthesis methods.

In vitro ADME profiling conducted per FDA guidelines shows excellent metabolic stability across multiple species' liver microsomes while maintaining consistent logP values between 4–5 across different formulations tested at Novartis' drug metabolism laboratories according to their open-access publication databases available through PubChem records linked via CAS number search interfaces.

• 948581-64-4(1H-Indole-3-carboxylicacid, 7-chloro-5-methyl-)
• 1000340-37-3(4-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid)
• 915140-96-4(6-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid)
• 920966-03-6(4-Chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid)
• 156270-06-3(1H-Pyrrolo[2,3-b]pyridine-3-carboxylic acid)
• 866541-71-1(Benzoic acid, 4-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-)
• 866541-73-3(3-Pyridinecarboxylic acid, 6-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-)
• 954112-61-9(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde)
• 1000340-12-4(5-Chloro-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid)
• 155735-02-7(6-Chloroimidazo[1,2-a]pyridine-8-carboxylic acid)